Header Graphic


Patients suffering from Parkinson's disease and non-trauma induced epilepsy have been treated with pT-MT for more than 20 years.  Hundreds of patients have been treated with this unique and safe technique by Dr. Photios Anninos at the University of Thrace, Department of Medicine, Medical Physics Sector, Alexandroupolis, Greece.

In the photo at the right, Dr. Anninos is adjusting a 122 channel liquid helium cooled Superconducting Quantum Interference Device (SQUID) to obtain magnetoencephalogram (MEG) data for a Parkinson's disease patient who has just been treated with pT-MT.  This system provides the capability for whole-brain real time monitoring and recording.

A Parkinson's disease patient (photo at the right) is shown wearing the pT-MT helmet, containing magnetic field coils linked to a low current signal source.  The patient is treated with pT magnetic flux densities at frequencies that are close to the patients alpha rhythm frequency (8 Hz to 13 Hz).  The alpha rhythm frequency for each patient is determined by MEG measurements with the SQUID using a Fourier statistical analysis of the MEG values.  The pT-MT system was developed by Professors P. Anninos and N. Tsagas.   

It appears that Parkinson's disease is not just one specific health problem; as it seems to have subdivisions.  Some patients can acquire a Parkinson's disease condition following a viral infection, trauma or atherosclerotic complications.  Others may have a Parkinson's condition induced by a medication or a neurotoxic heavy metal contaminant (oxidative stress occurs, due to high levels of manganese or iron).  There are some genetic predisposition and/or neurotransmitter deficiency factors.  Parkinson's disease can also exhibit some similarities with other neurological disorders such as benign essential tremor, Wilson's disease (inherited defect in excretion of copper by liver), Huntington's disease (inherited, single faulty gene in chromosome # 4) or Alzheimer's disease (possible genetic factors, history of head trauma, neurotransmitter/hormonal deficiencies, heavy metal toxins including aluminum and mercury).

MEG data taken for a Parkinson's disease patient are shown in the two photos at the right.  The top photo shows MEG data before the patient was treated with pT-MT, indicating very abnormal MEG activity in the right half of the photo.  Five hours after the initial pT-MT treatment, the lower photo shows a significant attenuation of abnormal MEG activity in the right half portion, and this was followed by an increase in low frequency brain activity components.  The patient's tremors decreased noticeably.  Also, the patient reported a reduction in muscular aches along with coordination and visiospatial improvements. 

Over the past 20 years, more than 85% of the epilepsy patients responsed to pT-MT treatment.  More than 75% of the Parkinson's disease patients responded to pT-MT.  For Parkinson's patients, pT-MT treatment results can vary considerably.  However, many Parkinson's patients, treated with pT-MT,show a significant improvement (significant reduction of tremors, increased energy, more natural facial expression, significant speech improvements, straight posture, better coordination, no further need for a wheel chair or cane, playing golf again, etc.).  Some Parkinson's patients, treated with pT-MT, show moderate improvement (some reduction of tremors, better coordination, some increase in energy, some improvement in speech, resume light exercise work outs, etc.).

Initial indicators of therapeutic efficacy include the patient's ability to draw a spiral on a piece of paper and reduction or elimination of specific tremors.  Even after the observed tremors cease, some patients report the sensation of a "phantom" tremor that lasts for awhile.

Additional information can be obtained from the following website:


From:  P. Anninos, et. al., International Journal of Neuroscience, Vol. 60, 1991; R. Sandyk, P. Anninos, N. Tsagas and K. Derpapas, International Journal of Neuroscience, Vol. 63, 1992; R. Sandyk and P. Anninos, International Journal of Neuroscience, Vol. 66, 1992; P. Anninos, et. al., Brain Topography, Vol. 13, 2000; S. Tofani, et. al., Bioelectromagnetics, Vol. 22, 2001; P. Anninos, et.al., Proceedings of Biological Effects of Electromagnetic Fields, 2nd International Workshop, Rhodes, Greece, 2002; G. D. O'Clock, German Journal of Oncology, Vol. 35, 2003; Anninos, et. al., Brain Topography, Vol. 16, 2003; G.D. O'Clock, Electrotherapeutic Devices: Principles, Design and Applications, Boston, MA (2007).